Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 1.00 |
| ▸ | MAPT | P10636 | 3/20 | 1.00 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 1.00 |
| ▸ | MEN1 | O00255 | 1/20 | 1.00 |
| ▸ | TP53 | P04637 | 1/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 1/20 | 1.00 |
| ▸ | CYP2C9 | P11712 | 1/20 | 1.00 |
| ▸ | HPGD | P15428 | 1/20 | 1.00 |
| ▸ | ALOX15 | P16050 | 1/20 | 1.00 |
| ▸ | CYP2C19 | P33261 | 1/20 | 1.00 |
| ▸ | KMT2A | Q03164 | 1/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 1.00 |
| ▸ | SNCA | P37840 | 1/20 | 0.59 |
| ▸ | CA12 | O43570 | 1/20 | 0.59 |
| ▸ | CA1 | P00915 | 1/20 | 0.59 |
| ▸ | CA2 | P00918 | 1/20 | 0.59 |
| ▸ | TYR | P14679 | 1/20 | 0.59 |
| ▸ | CA7 | P43166 | 1/20 | 0.59 |
| ▸ | CA9 | Q16790 | 1/20 | 0.59 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.59 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29727537 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL343785 | 1.00 | ALDH1A1 (1.00) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL28222024 | 0.98 | MAPT (0.97) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL7573821 | 0.86 | ALDH1A1 (0.76) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL29886427 | 0.86 | ALDH1A1 (0.76) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL9120628 | 0.85 | APP (0.76) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL9120636 | 0.85 | APP (0.76) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL27736560 | 0.85 | ALDH1A1 (0.73) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL11823438 | 0.83 | MAPT (0.71) | ALDH1A1MAPTKDM4EMEN1TP53 | |
| SCHEMBL544907 | 0.83 | MAPT (0.71) | ALDH1A1MAPTKDM4EMEN1TP53 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 267 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| WO-2025049554-A1 | HIF1A OR GLUT1 INHIBITION IN INFLAMMATORY SKIN DISEASES | NEW YORK UNIVERSITY (US) | 2025-03-06 | — | — | WO | claimed |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2022-07-19 | — | — | US | claimed |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | VERTEX PHARMACEUTICALS INCORPORATED | 2020-10-29 | — | — | US | claimed |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. (US) | 2020-08-11 | — | — | US | claimed |
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | BIOMED VALLEY DISCOVERIES, INC. | 2019-05-02 | — | — | US | claimed |
| EP-2966166-B1 | PROMOTER OF DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO MYOCARDIUM, WHICH COMPRISES EGF RECEPTOR INHIBITOR | UNIV KYOTO (JP) | 2019-04-03 | — | — | EP | claimed |
| EP-2966166-A1 | PROMOTER OF DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO MYOCARDIUM, WHICH COMPRISES EGF RECEPTOR INHIBITOR | Kyoto University (JP) | 2016-01-13 | — | — | EP | claimed |
| US-20160002600-A1 | COMPOSITION FOR PROMOTING CARDIAC DIFFERENTIATION OF PLURIPOTENT STEM CELL COMPRISING EGFR INHIBITOR | KYOTO UNIVERSITY (JP) | 2016-01-07 | — | — | US | claimed |
| WO-2014136519-A1 | PROMOTER OF DIFFERENTIATION OF PLURIPOTENT STEM CELL INTO MYOCARDIUM, WHICH COMPRISES EGF RECEPTOR INHIBITOR | 国立大学法人京都大学 (JP) | 2014-09-12 | — | — | WO | claimed |
| EP-0809493-B1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | US HEALTH (US) | 2002-09-11 | — | — | EP | claimed |
| EP-0809493-A1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-12-03 | — | — | EP | claimed |
| US-5610185-A | Method for the treatment of hyperproliferative epithelial skin diseases by topical application of hydroxylated aromatic protein cross-linking compounds | THE UNITED STATES OF AMERICA AS REPRESENTED BY THE DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1997-03-11 | — | — | US | claimed |
| WO-1996025159-A1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-22 | — | — | WO | claimed |
| JP-3109323-A | — | — | None | — | — | JP | disclosed |
| WO-2026087699-A1 | NEW TREATMENT OF NON-SMALL CELL LUNG CANCER | PIERRE FABRE MEDICAMENT (FR) | 2026-04-30 | — | — | WO | disclosed |
| EP-4653054-A2 | C. NOVYI FOR THE TREATMENT OF SOLID TUMORS IN HUMANS | Biomed Valley Discoveries, Inc. (US) | 2025-11-26 | — | — | EP | disclosed |
| WO-1996025159-A1 | A METHOD FOR THE TREATMENT OF HYPERPROLIFERATIVE EPITHELIAL SKIN DISEASES BY TOPICAL APPLICATION OF HYDROXYLATED AROMATIC PROTEIN CROSS-LINKING COMPOUNDS | THE GOVERNMENT OF THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES (US) | 1996-08-22 | — | — | WO | disclosed |
| WO-1996018103-A1 | INHIBITION OF GLIAL CELL PROLIFERATION | THE SCRIPPS RESEARCH INSTITUTE (US) | 1996-06-13 | — | — | WO | disclosed |
| WO-1995013820-A1 | USE OF AN AGENT WHICH MODULATES TYROSINE PHOSPHORYLATION FOR MODULATING THE PERMEABILITY OF A PSYCHOLOGICAL BARRIER | EISAI CO., LTD. (JP) | 1995-05-26 | — | — | WO | disclosed |
| JP-H03109323-A | ANTICANCER AGENT | MICROBIAL CHEM RES FOUND | 1991-05-09 | — | — | JP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190127348-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ALDH1A1 781/4885MAPT 2217/4885KDM4E 4194/4885 |
| US-10738027-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ALDH1A1 781/4885MAPT 2217/4885KDM4E 4194/4885 |
| US-20200339531-A1 | CRYSTALLINE FORMS OF C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ALDH1A1 781/4885MAPT 2217/4885KDM4E 4194/4885 |
| US-11390600-B2 | Crystalline forms of C21H22Cl2N4O2 | CYP2F1, H4C1; H4C2; H4C3; H4C4; H4C5; H4C6; H4C8; H4C9; H4C11; H4C12; H4C13; H4C14; H4C15; H4C16, CA4 | ALDH1A1 781/4885MAPT 2217/4885KDM4E 4194/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.